Replies to post #13910 on Momenta Pharmaceuticals, Inc. (MNTA)

[GrthzGd]

As I recall, MNTA's revenues dropped once its Enoxaparin share went from 45% of profits to the straight royalty of 10-12% on Sandoz' net sales. So, unless that was all due to the price drop caused by Watson's entry, this should represent a revenue improvement.